LYRA Form 4: Perceptive affiliates report multi-day insider sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Lyra Therapeutics (LYRA): insider transactions reported. Perceptive-affiliated entities disclosed multiple open-market sales of common stock on 11/11/2025, 11/12/2025, and 11/13/2025. Reported weighted average prices were $4.3146, $4.0594, and $3.9001, respectively.
Following these transactions, the filing shows Perceptive Life Sciences Master Fund, Ltd. with 124,859 shares and Perceptive LS (A), LLC with 14,026 shares, each held indirectly. The filing notes that prices reflect weighted averages over multiple trades and that the reporting persons disclaim beneficial ownership beyond their indirect pecuniary interests.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 45,875 shares ($182,515)
Net Sell
6 txns
Insider
PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, Perceptive LS (A), LLC, EDELMAN JOSEPH
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold
45,875 shs ($183K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 28,597 | $3.9001 | $112K |
| Sale | Common Stock | 3,213 | $3.9001 | $13K |
| Sale | Common Stock | 7,862 | $4.0594 | $32K |
| Sale | Common Stock | 883 | $4.0594 | $4K |
| Sale | Common Stock | 4,783 | $4.3146 | $21K |
| Sale | Common Stock | 537 | $4.3146 | $2K |
Holdings After Transaction:
Common Stock — 124,859 shares (Indirect, See Footnotes)
Footnotes (1)
- The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. The securities reported in this row are held by the Master Fund. The securities reported in this row are held by Perceptive LS. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
FAQ
What insider activity did LYRA report on Form 4?
Affiliated Perceptive entities reported multiple open‑market sales of LYRA common stock on 11/11/2025, 11/12/2025, and 11/13/2025 at weighted average prices.
What prices were reported for the LYRA insider sales?
Weighted average prices were $4.3146 (11/11/2025), $4.0594 (11/12/2025), and $3.9001 (11/13/2025), each reflecting multiple transactions within disclosed ranges.
Who are the reporting persons in the LYRA Form 4?
Perceptive Advisors, LLC; Perceptive Life Sciences Master Fund, Ltd.; Perceptive LS (A), LLC; Perceptive LS GP, LLC; and Joseph Edelman.
Were these LYRA trades made under a Rule 10b5‑1 plan?
The form includes the standard 10b5‑1 checkbox text, but the excerpt does not indicate that the box was checked.
Did the filing report any derivative securities for LYRA?
No derivative securities were listed in Table II of the excerpt.
What ownership capacity was indicated for these LYRA holdings?
Holdings were reported as indirect, with disclaimers limiting beneficial ownership to indirect pecuniary interests.